Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.

Pharmacogenomics - 1 Apr 2009

Rodríguez-Antona Cristina, Gurwitz David, de Leon Jose, Llerena Adrián, Kirchheiner Julia, de Mesa Emma Gutiérrez, Ibarreta Dolores

Abstract excerpt

In order to ascertain data availability and feasibility for conducting cost-effectiveness studies in pharmacogenetics, and as part of a European Commission Joint Research Center, Institute for Prospective Technological Studies (JRC-IPTS) study, data concerning risperidone use and cytochrome P450 (CYP2D6) genotyping in medical care was collected in Germany, Spain and the USA, and are summarized in this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Germany

Share to Inactivation, Metabolic

Share to Mental Disorders

Share to Risperidone

Source

Identifiers

PMID: 19374522
DOI: 10.2217/pgs.09.15

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.PMID 19374522Read ↗

CYP2D6 polymorphisms and their influence on risperidone treatmentSemantic proximity Read ↗

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.Semantic proximity Read ↗

Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers.Semantic proximity Read ↗

Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients.Semantic proximity Read ↗

Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone.Semantic proximity Read ↗

Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?Semantic proximity Read ↗

A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia.Semantic proximity Read ↗

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment.Semantic proximity Read ↗

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.Semantic proximity Read ↗

Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets.Semantic proximity Read ↗

CYP2D6 Genotypes Do Not Affect Clozapine Levels in a Large, Multicenter Cohort: Time Has Come to Revise Food and Drug Administration's Clozapine Packet Insert.Semantic proximity Read ↗

Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.